Ubs Oconnor LLC Oric Pharmaceuticals, Inc. Transaction History

Ubs Oconnor LLC

$1.59 Billion
Q1 2024

A detailed history of Ubs Oconnor LLC transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 80,000 shares of ORIC stock, worth $804,800. This represents 0.07% of its overall portfolio holdings.

Number of Shares

80,000

Holding current value

$804,800

% of portfolio

0.07%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$8.04 - $16.03 $1.37 Million - $2.73 Million	-170,590 Reduced 64.87%	92,366 $1.27 Million
Q4 2023 Feb 14, 2024	SELL	$5.41 - $9.43 $479,033 - $834,988	-88,546 Reduced 25.19%	262,956 $2.42 Million
Q3 2023 Nov 14, 2023	SELL	$6.05 - $9.28 $60,500 - $92,800	-10,000 Reduced 2.77%	351,502 $2.13 Million
Q2 2023 Aug 14, 2023	BUY	$4.95 - $8.4 $1.79 Million - $3.04 Million	361,502 New	361,502 $2.81 Billion
Q1 2023 May 15, 2023	BUY	$4.26 - $6.75 $73,578 - $116,586	17,272 Added 5.0%	362,707 $2.07 Million

Q4 2022 Feb 14, 2023	BUY	$2.41 - $5.89 $5,863 - $14,330	2,433 Added 0.71%	345,435 $0
Q3 2022 Nov 14, 2022	SELL	$3.28 - $5.24 $59,213 - $94,597	-18,053 Reduced 5.0%	343,002 $1.1 Billion
Q2 2022 Aug 12, 2022	BUY	$2.7 - $7.07 $974,848 - $2.55 Million	361,055 New	361,055 $1.62 Million

Others Institutions Holding ORIC

# of Institutions

112

Shares Held

59.3M

Call Options Held

302K

Put Options Held

7.7K

Nextech Invest Ag

5.29M
Shares

$53.2 Million
13.59% of portfolio
Vr Adviser, LLC New York, NY

4.39M
Shares

$44.2 Million
5.19% of portfolio
Frazier Life Sciences Management, L.P. Menlo Park, CA

4.14M
Shares

$41.7 Million
2.99% of portfolio
Viking Global Investors LP

4M
Shares

$40.2 Million
0.21% of portfolio
Alkeon Capital Management LLC New York, NY

3.7M
Shares

$37.3 Million
0.09% of portfolio

View Full List

About Oric Pharmaceuticals, Inc.

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $398M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

More about ORIC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account